Bajoria S, Agarwal S A, White R, Zafar F, Williams G
Department of Urology, Hammersmith Hospital, London, UK.
Br J Urol. 1995 Mar;75(3):325-7. doi: 10.1111/j.1464-410x.1995.tb07343.x.
To assess the efficacy of the new, second generation UroLume (American Medical Systems) prostatic stent.
Forty-seven men with symptomatic and objective evidence of bladder outflow obstruction who were fit for a transurethral resection accepted, as an alternative, the insertion of a new prostatic stent which shortens less than its predecessor.
It was possible to insert the stent into 44 of the 47 men. All patients voided spontaneously following stent insertion. Thirty-three patients had their stent inserted either as a day case or with an overnight stay. Six patients were lost to follow-up and two died. Of the remaining 36 patients 22 have now been followed for 2 years, with a mean obstructive score of 1.6 (range 0-12), a mean irritative score of 2.5 (range 0-10) and a mean peak flow of 16.8 mL/s (range 3-31). Fourteen stents had to be removed; in the majority of cases this was because of stent migration or the development of epithelial hyperplasia within the lumen of the stent.
Because of the development of epithelial hyperplasia and stent migration in approximately one-third of men in this study, a third generation stent has now been developed. Before permanently implanted stents can be recommended for widespread use, the efficacy of new stents should be assessed in specialist units with large numbers of patients and adequate facilities for follow-up.
评估新一代UroLume（美国医疗系统公司）前列腺支架的疗效。
47名有膀胱出口梗阻症状及客观证据且适合经尿道切除术的男性，作为替代方案，接受了一种缩短程度小于其前代产品的新型前列腺支架植入。
47名男性中有44名成功植入支架。所有患者在支架植入后均能自主排尿。33名患者在日间手术或住院一晚后植入了支架。6名患者失访，2名患者死亡。在其余36名患者中，22名现已随访2年，平均梗阻评分为1.6（范围0 - 12），平均刺激评分为2.5（范围0 - 10），平均峰值尿流率为16.8 mL/s（范围3 - 31）。14个支架不得不被移除；在大多数情况下，这是由于支架移位或支架腔内上皮增生。
由于本研究中约三分之一的男性出现了上皮增生和支架移位，现已研发出第三代支架。在推荐永久性植入支架广泛使用之前，应在拥有大量患者和充足随访设施的专科单位评估新型支架的疗效。
